Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAJA K SIVAMANI

Allopathic & Osteopathic Physicians Dermatology

NPI
1811197478
CMS profile
355062
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$663,153.77

561 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $116,794.70 98
UCB, Inc. $101,505.09 140
Lilly USA, LLC $99,265.83 69
Galderma Laboratories, L.P. $79,699.70 47
PFIZER INC. $73,294.55 45
GENZYME CORPORATION $36,010.14 13
Regeneron Healthcare Solutions, Inc. $31,308.42 11
ABBVIE INC. $25,810.07 26
Eli Lilly and Company $19,844.21 18
Almirall LLC $17,200.00 11
LEO Pharma Inc. $13,337.11 12
E.R. Squibb & Sons, L.L.C. $11,752.99 6
Novartis Pharmaceuticals Corporation $10,016.20 27
The Daavlin Distributing Co $10,000.00 1
Janssen Biotech, Inc. $5,972.98 6
Arcutis Biotherapeutics, Inc. $3,983.69 7
Nielsen BioSciences, Inc. $3,625.00 1
SANOFI US SERVICES INC. $2,335.00 1
Insmed, Inc. $1,114.56 7
Amgen Inc. $97.56 5
Organon LLC $84.91 5
SUN PHARMACEUTICAL INDUSTRIES INC. $66.75 3
Cipher Pharmaceuticals US LLC $18.55 1
Botanix SB Inc $15.76 1

Page 4 of 12; records 151–200 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAJA K SIVAMANI

NPI 1811197478 · CMS profile ID 355062

Allopathic & Osteopathic Physicians / Dermatology

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 12; records 151–200 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAJA K SIVAMANI, NPI 1811197478, CMS profile ID 355062. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 12; records 151–200 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RAJA K SIVAMANI, NPI 1811197478, CMS profile ID 355062. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 12; records 151–200 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RAJA K SIVAMANI, NPI 1811197478, CMS profile ID 355062, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 12; records 151–200 of 561 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1811197478?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

561 matching records · $663,153.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 561 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 561.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $388.3010/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753975 CMS
Cipher Pharmaceuticals US LLC $18.5510/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250592314 CMS
UCB, Inc. $113.0610/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753957 CMS
UCB, Inc. $113.0610/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753959 CMS
UCB, Inc. $113.0610/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753961 CMS
UCB, Inc. $151.6210/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753963 CMS
UCB, Inc. $151.6210/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753965 CMS
UCB, Inc. $151.6210/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753967 CMS
UCB, Inc. $10.0010/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753943 CMS
UCB, Inc. $10.0010/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753945 CMS
UCB, Inc. $10.0010/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753947 CMS
UCB, Inc. $10.0010/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753949 CMS
UCB, Inc. $10.0010/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753951 CMS
UCB, Inc. $10.0010/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753953 CMS
UCB, Inc. $59.7110/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224753955 CMS
Incyte Corporation $2,250.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226027829 CMS
Incyte Corporation $4,500.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226028905 CMS
Incyte Corporation $4,500.0010/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226028915 CMS
LEO Pharma Inc. $1,200.0010/16/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1252036586 CMS
Novartis Pharmaceuticals Corporation $22.9110/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200523538 CMS
Novartis Pharmaceuticals Corporation $20.1110/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200523540 CMS
UCB, Inc. $84.9010/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224753935 CMS
UCB, Inc. $150.0810/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753937 CMS
UCB, Inc. $566.4110/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753939 CMS
UCB, Inc. $1,190.5410/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753941 CMS
Incyte Corporation $28.8610/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225983172 CMS
Janssen Biotech, Inc. $1,913.0010/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174768062 CMS
PFIZER INC. $885.4610/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1229659101 CMS
Incyte Corporation $750.0010/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225980506 CMS
ABBVIE INC. $1,725.0010/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204321371 CMS
Incyte Corporation $131.8610/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226025700 CMS
Incyte Corporation $953.2210/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226025716 CMS
PFIZER INC. $4,250.0010/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1229402964 CMS
Eli Lilly and Company $115.2210/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186789461 CMS
Eli Lilly and Company $197.4010/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186904130 CMS
Eli Lilly and Company $197.4010/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186917592 CMS
Eli Lilly and Company $754.4410/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186928992 CMS
Eli Lilly and Company $115.2210/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186928994 CMS
PFIZER INC. $1,036.0510/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1229334697 CMS
UCB, Inc. $15.0010/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753933 CMS
Arcutis Biotherapeutics, Inc. $22.5510/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252367147 CMS
Incyte Corporation $4,500.0010/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225980504 CMS
Incyte Corporation $2,250.0010/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225982834 CMS
Incyte Corporation $28.0110/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226025698 CMS
Incyte Corporation $814.2510/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226025732 CMS
Incyte Corporation $120.4310/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226027665 CMS
Incyte Corporation $906.7610/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226028139 CMS
Incyte Corporation $4,500.0010/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226028917 CMS
UCB, Inc. $6.6610/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753897 CMS
UCB, Inc. $6.6610/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224753899 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,283.71 30
PY2020 $44,256.52 12
PY2021 $17,246.74 51
PY2022 $137,702.12 165
PY2023 $432,306.21 398
PY2024 $584,800.38 520
PY2025 $663,153.77 561

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $57,501.69 2
PY2025 Principal investigator $4,004,892.48 257
PY2024 Recipient $129,213.85 11
PY2024 Principal investigator $3,660,171.03 220
PY2023 Recipient $324.09 1
PY2023 Principal investigator $1,103,523.70 110
PY2022 Principal investigator $416,468.20 61
PY2021 Principal investigator $432,972.16 63
PY2020 Recipient $2,948.54 2
PY2020 Principal investigator $317,891.91 48
PY2019 Recipient $4,530.13 23
PY2019 Principal investigator $33,261.22 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

259 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534607
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534609
Principal investigator 1 PFIZER INC. $7,771.29 12/31/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228751501
Principal investigator 1 Janssen Research & Development, LLC $31,641.00 12/25/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175176528
Principal investigator 1 Janssen Research & Development, LLC $2,291.00 12/25/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415698
Principal investigator 1 ABBVIE INC. $5,149.10 12/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202532060
Principal investigator 1 Janssen Research & Development, LLC $3,782.00 12/22/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175176518
Principal investigator 1 Janssen Research & Development, LLC $8,792.00 12/19/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415749
Principal investigator 1 PFIZER INC. $5,981.86 12/17/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228736878
Principal investigator 1 ABBVIE INC. $1,151.16 12/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530250
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,700.00 12/09/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) No dispute reported 06/30/2026 1220802350
Principal investigator 1 ABBVIE INC. $11,131.05 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202528620
Principal investigator 1 ABBVIE INC. $36,808.45 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528622
Principal investigator 1 ABBVIE INC. $8,391.25 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202528624
Principal investigator 1 ABBVIE INC. $14,792.35 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202528830
Principal investigator 1 ABBVIE INC. $15,057.90 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202528832
Principal investigator 1 ABBVIE INC. $454.95 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202528834
Principal investigator 1 ABBVIE INC. $1,678.10 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202528836
Principal investigator 1 ABBVIE INC. $18,974.10 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202528838
Principal investigator 1 ABBVIE INC. $26,833.88 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202528928
Principal investigator 1 PFIZER INC. $5,329.14 12/03/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228734628
Principal investigator 1 PFIZER INC. $10,938.55 11/26/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228739284
Principal investigator 1 PFIZER INC. $1,746.23 11/25/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228724508
Principal investigator 1 ABBVIE INC. $4,735.95 11/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202524822
Principal investigator 1 ABBVIE INC. $11,307.37 11/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202524824
Principal investigator 1 ABBVIE INC. $515.70 11/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202524832
Principal investigator 1 ABBVIE INC. $2,299.04 11/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524858
Principal investigator 1 ABBVIE INC. $1,054.52 11/19/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202524640
Principal investigator 1 ABBVIE INC. $2,562.40 11/13/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202524115
Principal investigator 1 ABBVIE INC. $15,020.82 11/13/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202524131
Principal investigator 1 ABBVIE INC. $5,007.30 11/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522055
Principal investigator 1 ABBVIE INC. $5,138.25 11/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202522057
Principal investigator 1 ABBVIE INC. $16,251.30 11/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522183
Principal investigator 1 ABBVIE INC. $44,453.80 11/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522185
Principal investigator 1 PFIZER INC. $3,093.53 11/05/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228729661
Principal investigator 1 ABBVIE INC. $13,316.88 11/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520447
Principal investigator 1 ABBVIE INC. $37,237.65 11/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202520449
Principal investigator 1 ABBVIE INC. $12,630.40 11/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520469
Principal investigator 1 Eli Lilly and Company $17,182.00 11/04/2025 Non-covered Recipient Entity
NORCAL MEDICAL RESEARCH INC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187885068
Principal investigator 1 Eli Lilly and Company $6,560.00 11/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187881624
Principal investigator 1 Janssen Research & Development, LLC $1,710.00 11/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415717
Principal investigator 1 Janssen Research & Development, LLC $1,926.00 10/31/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415730
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235996589
Principal investigator 1 PFIZER INC. $1,746.23 10/29/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,180.00 10/28/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220802338
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,143.62 10/28/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190312857
Principal investigator 1 Eli Lilly and Company $6,560.00 10/27/2025 Non-covered Recipient Entity
NORCAL MEDICAL RESEARCH INC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187886196
Principal investigator 1 Janssen Research & Development, LLC $12,440.00 10/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175176536
Principal investigator 1 PFIZER INC. $1,584.23 10/22/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741432
Principal investigator 1 Janssen Research & Development, LLC $13,000.00 10/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175176553
Principal investigator 1 Janssen Research & Development, LLC $313.00 10/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415634
Principal investigator 1 ABBVIE INC. $712.80 10/17/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202517425
Principal investigator 1 ABBVIE INC. $6,455.85 10/15/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202516933
Principal investigator 1 ABBVIE INC. $2,469.79 10/15/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202516935
Principal investigator 1 ABBVIE INC. $1,132.50 10/15/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202516937
Principal investigator 1 ABBVIE INC. $4,587.60 10/15/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202516975
Principal investigator 1 ABBVIE INC. $3,339.90 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202515255
Principal investigator 1 ABBVIE INC. $20,391.45 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202515437
Principal investigator 1 ABBVIE INC. $2,091.90 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202515439
Principal investigator 1 ABBVIE INC. $29,267.21 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202515441
Principal investigator 1 ABBVIE INC. $4,372.81 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202515443
Principal investigator 1 ABBVIE INC. $50,244.10 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515445
Principal investigator 1 ABBVIE INC. $1,470.20 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202515653
Principal investigator 1 ABBVIE INC. $9,634.50 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515657
Principal investigator 1 Eli Lilly and Company $3,000.00 10/09/2025 Non-covered Recipient Entity
OSMAN DERMATOLOGY
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889900
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $68,502.10 10/08/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220802340
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,404.68 10/08/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190312859
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $38,638.50 10/07/2025 Non-covered Recipient Entity
Northwestern University
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220796487
Principal investigator 1 PFIZER INC. $62.10 10/04/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228740696
Principal investigator 1 ABBVIE INC. $13,248.00 10/01/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
Skin Care No dispute reported 06/30/2026 1202512950
Principal investigator 1 Janssen Research & Development, LLC $15,414.00 09/29/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175176512
Principal investigator 1 Janssen Research & Development, LLC $6,840.00 09/29/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415660
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 09/29/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415680
Principal investigator 1 PFIZER INC. $2,888.33 09/26/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228753363
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,201.00 09/23/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) No dispute reported 06/30/2026 1220802348
Principal investigator 1 Janssen Research & Development, LLC $698.00 09/22/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415621
Principal investigator 1 PFIZER INC. $6,218.79 09/19/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228768563
Principal investigator 1 PFIZER INC. $53,231.16 09/12/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228750480
Principal investigator 1 ABBVIE INC. $3,160.95 09/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202510598
Principal investigator 1 ABBVIE INC. $515.70 09/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202510614
Principal investigator 1 ABBVIE INC. $17,610.01 09/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510616
Principal investigator 1 ABBVIE INC. $8,656.40 09/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202510618
Principal investigator 1 ABBVIE INC. $1,404.93 09/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202510754
Principal investigator 1 ABBVIE INC. $3,952.05 09/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202510756
Principal investigator 1 Janssen Research & Development, LLC $18,535.00 09/08/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175176545
Principal investigator 1 ABBVIE INC. $4,330.95 09/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202508488
Principal investigator 1 ABBVIE INC. $45,354.35 09/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202508510
Principal investigator 1 ABBVIE INC. $3,208.05 09/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202508610
Principal investigator 1 ABBVIE INC. $29,426.70 09/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202508612
Principal investigator 1 ABBVIE INC. $17,236.65 09/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202507175
Principal investigator 1 ABBVIE INC. $1,470.20 09/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202507241
Principal investigator 1 ABBVIE INC. $26,408.44 09/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202508154
Principal investigator 1 ABBVIE INC. $25,029.18 09/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202508156
Principal investigator 1 ABBVIE INC. $7,559.18 08/29/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202506529
Recipient Nielsen BioSciences, Inc. $40,152.06 08/28/2025 Covered Recipient Physician CFW--3A No dispute reported 06/30/2026 1215524931
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,195.00 08/25/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) No dispute reported 06/30/2026 1220802346
Principal investigator 1 Janssen Research & Development, LLC $2,557.00 08/25/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415735
Principal investigator 1 PFIZER INC. $7,552.60 08/23/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228753355
Principal investigator 1 ABBVIE INC. $1,537.65 08/19/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202505055
Principal investigator 1 LEO Pharma AS $1,000.00 08/13/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB No dispute reported 06/30/2026 1251993671
Recipient Eli Lilly and Company $17,349.63 08/08/2025 Covered Recipient Physician A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187872865
Principal investigator 1 ABBVIE INC. $3,172.60 08/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202503667
Principal investigator 1 ABBVIE INC. $12,347.15 08/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503669
Principal investigator 1 ABBVIE INC. $8,648.25 08/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202503693
Principal investigator 1 ABBVIE INC. $2,122.27 08/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202503697
Principal investigator 1 ABBVIE INC. $10,110.45 08/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502320
Principal investigator 1 ABBVIE INC. $87,856.95 08/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502374
Principal investigator 1 ABBVIE INC. $8,979.90 08/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202502376
Principal investigator 1 ABBVIE INC. $7,280.25 08/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501126
Principal investigator 1 ABBVIE INC. $43,587.15 08/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202501194
Principal investigator 1 ABBVIE INC. $15,089.57 08/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501196
Principal investigator 1 PFIZER INC. $2,888.33 08/05/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228767219
Principal investigator 1 Amgen Inc. $12,175.00 08/01/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) No dispute reported 06/30/2026 1246642812
Principal investigator 1 Janssen Research & Development, LLC $2,557.00 08/01/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415705
Principal investigator 1 Janssen Research & Development, LLC $42,160.00 07/31/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175176503
Principal investigator 1 PFIZER INC. $5,593.74 07/29/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228763962
Principal investigator 1 Janssen Research & Development, LLC $1,443.00 07/28/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415686
Principal investigator 1 ABBVIE INC. $4,023.00 07/22/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202499082
Principal investigator 1 ABBVIE INC. $2,281.50 07/17/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202498696
Principal investigator 1 PFIZER INC. $12,739.27 07/17/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228771625
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,096.00 07/15/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) No dispute reported 06/30/2026 1220802344
Principal investigator 1 ABBVIE INC. $3,060.65 07/10/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202497886
Principal investigator 1 ABBVIE INC. $513.00 07/10/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497888
Principal investigator 1 ABBVIE INC. $6,786.45 07/10/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202497892
Principal investigator 1 ABBVIE INC. $17,456.15 07/10/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202497894
Principal investigator 1 ABBVIE INC. $723.60 07/10/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202497896
Principal investigator 1 ABBVIE INC. $19,487.10 07/08/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497182
Principal investigator 1 ABBVIE INC. $13,447.95 07/08/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497184
Principal investigator 1 ABBVIE INC. $2,728.00 07/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202496944
Principal investigator 1 ABBVIE INC. $57,050.60 07/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202494921
Principal investigator 1 ABBVIE INC. $1,678.10 07/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202494923
Principal investigator 1 ABBVIE INC. $18,445.35 07/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202494955
Principal investigator 1 ABBVIE INC. $22,675.61 07/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202495627
Principal investigator 1 ABBVIE INC. $17,533.47 07/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495893
Principal investigator 1 ABBVIE INC. $631.20 07/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202495895
Principal investigator 1 PFIZER INC. $14,500.39 07/02/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228784027
Principal investigator 1 Janssen Research & Development, LLC $5,114.00 06/27/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415646
Principal investigator 1 ABBVIE INC. $1,657.80 06/26/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202493233
Principal investigator 1 Janssen Research & Development, LLC $2,291.00 06/26/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415628
Principal investigator 1 ABBVIE INC. $1,139.40 06/17/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202491789
Principal investigator 1 ABBVIE INC. $6,403.65 06/17/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202491855
Principal investigator 1 ABBVIE INC. $4,097.25 06/17/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202491857
Principal investigator 1 ABBVIE INC. $4,315.95 06/17/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202491859
Principal investigator 1 ABBVIE INC. $5,265.00 06/16/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202491677
Principal investigator 1 Boehringer Ingelheim International GmbH $217.50 06/16/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) No dispute reported 06/30/2026 1220691767
Principal investigator 1 ABBVIE INC. $3,345.30 06/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202490029
Principal investigator 1 ABBVIE INC. $7,130.70 06/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202490031
Principal investigator 1 ABBVIE INC. $1,212.30 06/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202490067
Principal investigator 1 ABBVIE INC. $21,173.55 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202487737
Principal investigator 1 ABBVIE INC. $17,433.75 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202487761
Principal investigator 1 ABBVIE INC. $14,989.80 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487765
Principal investigator 1 ABBVIE INC. $21,289.93 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202488679
Principal investigator 1 ABBVIE INC. $1,678.10 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202488697
Principal investigator 1 ABBVIE INC. $9,800.24 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202489349
Principal investigator 1 ABBVIE INC. $24,261.30 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202489351
Principal investigator 1 ABBVIE INC. $11,000.00 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202489427
Principal investigator 1 PFIZER INC. $1,821.23 05/30/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228765035
Principal investigator 1 Janssen Research & Development, LLC $5,075.00 05/26/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415666
Principal investigator 1 ABBVIE INC. $1,637.55 05/22/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202485849
Principal investigator 1 PFIZER INC. $26,663.86 05/16/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228774225
Principal investigator 1 ABBVIE INC. $5,463.90 05/15/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202484937
Principal investigator 1 ABBVIE INC. $7,945.75 05/15/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202485191
Principal investigator 1 ABBVIE INC. $951.15 05/15/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202485193
Principal investigator 1 Boehringer Ingelheim International GmbH $217.50 05/15/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220691765
Principal investigator 1 ABBVIE INC. $5,988.75 05/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202483215
Principal investigator 1 ABBVIE INC. $11,479.18 05/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483225
Principal investigator 1 ABBVIE INC. $12,375.15 05/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483231
Principal investigator 1 ABBVIE INC. $69,387.90 05/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483997
Principal investigator 1 ABBVIE INC. $67,432.65 05/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483999
Principal investigator 1 ABBVIE INC. $2,940.40 05/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202481147
Principal investigator 1 ABBVIE INC. $26,247.39 05/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482237
Principal investigator 1 PFIZER INC. $5,577.52 05/03/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228777085
Principal investigator 1 Eli Lilly and Company $152,606.00 04/29/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187884016
Principal investigator 1 Janssen Research & Development, LLC $1,949.00 04/28/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415670
Principal investigator 1 Janssen Research & Development, LLC $15,521.00 04/25/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415640
Principal investigator 1 ABBVIE INC. $904.55 04/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202478872
Principal investigator 1 ABBVIE INC. $515.70 04/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202478896
Principal investigator 1 ABBVIE INC. $922.05 04/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202478900
Principal investigator 1 ABBVIE INC. $4,965.30 04/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202478960
Principal investigator 1 ABBVIE INC. $7,021.91 04/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202478996
Principal investigator 1 ABBVIE INC. $3,000.00 04/23/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
SKINMEDICA STUDY No dispute reported 06/30/2026 1202478618
Principal investigator 1 ABBVIE INC. $9,697.76 04/17/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE & RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 1202477381
Principal investigator 1 ABBVIE INC. $3,775.95 04/14/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202476240
Principal investigator 1 ABBVIE INC. $13,860.60 04/14/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202476244
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,731.80 04/09/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220802336
Principal investigator 1 PFIZER INC. $7,161.75 04/09/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228796995
Principal investigator 1 ABBVIE INC. $1,830.60 04/08/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202474876
Principal investigator 1 ABBVIE INC. $58,243.90 04/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
SKINMEDICA STUDY No dispute reported 06/30/2026 1202474701
Principal investigator 1 ABBVIE INC. $5,000.00 04/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
SKINMEDICA STUDY No dispute reported 06/30/2026 1202474703
Principal investigator 1 ABBVIE INC. $24,648.00 04/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
SKINMEDICA STUDY No dispute reported 06/30/2026 1202474708
Principal investigator 1 ABBVIE INC. $36,227.10 04/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
SKINMEDICA STUDY No dispute reported 06/30/2026 1202474711
Principal investigator 1 ABBVIE INC. $1,844.10 04/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202474366
Principal investigator 1 ABBVIE INC. $12,624.15 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202469627
Principal investigator 1 ABBVIE INC. $28,644.30 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202469666
Principal investigator 1 ABBVIE INC. $16,428.17 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202469720
Principal investigator 1 ABBVIE INC. $20,726.92 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202469723
Principal investigator 1 ABBVIE INC. $3,107.20 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202470153
Principal investigator 1 ABBVIE INC. $21,728.85 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202470157
Principal investigator 1 ABBVIE INC. $3,547.45 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470568
Principal investigator 1 ABBVIE INC. $37,377.15 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202470571
Principal investigator 1 ABBVIE INC. $6,534.00 03/27/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202466803
Principal investigator 1 ABBVIE INC. $10,074.46 03/27/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202466827
Principal investigator 1 Janssen Research & Development, LLC $2,774.00 03/27/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415711
Principal investigator 1 PFIZER INC. $8,745.98 03/22/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228794890
Principal investigator 1 ABBVIE INC. $2,569.05 03/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202465155
Principal investigator 1 ABBVIE INC. $2,777.05 03/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202465179
Principal investigator 1 ABBVIE INC. $16,463.35 03/18/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202464172
Principal investigator 1 ABBVIE INC. $65,337.30 03/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462353
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $581.10 03/11/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220802334
Principal investigator 1 ABBVIE INC. $45,456.70 03/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460411
Principal investigator 1 ABBVIE INC. $30,362.25 03/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202461000
Principal investigator 1 ABBVIE INC. $37,736.43 03/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202461116
Principal investigator 1 ABBVIE INC. $20,140.00 03/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202461120
Principal investigator 1 ABBVIE INC. $27,258.65 03/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202461124
Principal investigator 1 ABBVIE INC. $4,304.55 03/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202461303
Principal investigator 1 ABBVIE INC. $12,397.70 03/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202457343
Principal investigator 1 ABBVIE INC. $824.00 03/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202457813
Principal investigator 1 ABBVIE INC. $6,484.05 03/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457997
Principal investigator 1 PFIZER INC. $4,384.14 03/04/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228780351
Principal investigator 1 Janssen Research & Development, LLC $5,895.00 03/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415742
Principal investigator 1 ABBVIE INC. $6,923.00 02/27/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202454518
Principal investigator 1 ABBVIE INC. $5,585.50 02/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202453649
Principal investigator 1 ABBVIE INC. $1,273.55 02/20/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202453094
Principal investigator 1 ABBVIE INC. $11,760.70 02/13/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202451365
Principal investigator 1 ABBVIE INC. $10,297.80 02/13/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202451417
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,962.20 02/12/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235996591
Principal investigator 1 ABBVIE INC. $4,057.75 02/11/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202450531
Principal investigator 1 PFIZER INC. $9,244.15 02/11/2025 Non-covered Recipient Entity
Integrative Skin Science and Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228761282
Principal investigator 1 Janssen Research & Development, LLC $9,368.00 02/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415724
Principal investigator 1 ABBVIE INC. $12,238.05 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448762
Principal investigator 1 ABBVIE INC. $2,308.15 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202448766
Principal investigator 1 ABBVIE INC. $24,475.91 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202448769
Principal investigator 1 ABBVIE INC. $5,452.85 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448778
Principal investigator 1 ABBVIE INC. $6,476.85 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202448871
Principal investigator 1 ABBVIE INC. $10,136.55 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202448875
Principal investigator 1 ABBVIE INC. $87,736.14 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202448909
Principal investigator 1 ABBVIE INC. $31,640.40 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202449250
Principal investigator 1 ABBVIE INC. $19,929.99 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202449254
Principal investigator 1 ABBVIE INC. $12,105.85 02/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202445669
Principal investigator 1 Janssen Research & Development, LLC $69.00 02/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415652
Principal investigator 1 Amgen Inc. $122,617.86 01/30/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) No dispute reported 06/30/2026 1246642820
Principal investigator 1 ABBVIE INC. $11,167.45 01/28/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441625
Principal investigator 1 Eli Lilly and Company $3,377.51 01/27/2025 Non-covered Recipient Entity
OSMAN DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187885242
Principal investigator 1 Janssen Research & Development, LLC $6,414.00 01/24/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEAR CH
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415692
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,349.59 01/21/2025 Non-covered Recipient Entity
Integrative Skin Science And Research - Location 2
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235996585
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,436.31 01/21/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235996587
Principal investigator 1 Eli Lilly and Company $86,380.00 01/21/2025 Non-covered Recipient Entity
OSMAN DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187887480
Principal investigator 1 ABBVIE INC. $20,390.80 01/16/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202439503
Principal investigator 1 ABBVIE INC. $696.60 01/14/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202438466
Principal investigator 1 ABBVIE INC. $688.00 01/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202437699
Principal investigator 1 ABBVIE INC. $188.98 01/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202437026
Principal investigator 1 Amgen Inc. $25,405.37 01/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246642825
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,361.50 01/07/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220802332
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,232.00 01/06/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) No dispute reported 06/30/2026 1220802342
Principal investigator 1 ABBVIE INC. $4,528.80 01/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202435198
Principal investigator 1 ABBVIE INC. $4,572.10 01/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202435306
Principal investigator 1 ABBVIE INC. $3,356.20 01/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESERCH
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202435665
Principal investigator 1 Amgen Inc. $567,196.84 01/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE AND RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246642816
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $581.10 01/02/2025 Non-covered Recipient Entity
Integrative Skin Science And Research
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220802330